



## Zosyn<sup>®</sup> (piperacillin/tazobactam) – New warning

- On May 5, 2017, the [FDA approved](#) an update to the *Warnings and Precautions* section of the [Zosyn \(piperacillin/tazobactam\)](#) drug label, regarding nephrotoxicity in critically ill patients.
- Zosyn is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a  $\beta$ -lactamase inhibitor, tazobactam, indicated for the treatment of patients with certain moderate to severe infections caused by susceptible isolates of bacteria.
- The use of Zosyn was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients.
  - Based on this study, alternative treatment options should be considered in the critically ill population. If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with Zosyn.
- Drug interaction information for Zosyn and vancomycin was also added to the *Warnings and Precautions* section stating that combined use of these two drugs may be associated with an increased incidence of acute kidney injury.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.